Adrucil (fluorouracil)

Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Adrucil is an analog of pyrimidine and acts as an antineoplastic agent that interferes with DNA and RNA synthesis. Its metabolite (F-dUMP) inhibits thymidylate synthetase, thus depleting thymidine triphosphate (a necessary component of DNA synthesis).

Preauthorization Criteria: Treatment of breast cancer, colon cancer, rectal cancer, pancreatic cancer, and stomach (gastric) cancer

Off Label Uses: Anal cancer; Bladder cancer; Cervical cancer; Esophageal cancer; Head and neck cancer; Hepatobiliary cancers; Neuroendocrine tumors; Penile cancer (metastatic); Thymic cancers; Unknown primary cancer

NOTE: fluorouracil injection should be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and who is well versed in the use of potent antimetabolites. Because of the possibility of severe toxic reactions, it is recommended that patients be hospitalized at least during the initial course of therapy.

Dosing: refer to product literature for dosing for each specific disease and for renal or hepatic failure; is commonly used in combination with other chemotherapeutic agents palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas.

How Supplied:

Adrucil: 500 mg/10 mL (10 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)

Generic: 500 mg/10 mL (10 mL); 1 g/20 mL (20 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)

Precautions: agranulocytosis; leukopenia; thrombocytopenia; CNS (cerebellar syndrome, altered mental status); Hand-foot syndrome; cardiovascular (arrhythmia, angina, acute MI, CVA)

Drug Interactions: strongly inhibits CYP2C9 and effects levels of those drugs metabolized by this cytochrome P450 enzyme (see product literature); enhances the immunosuppressant effect of
other medications;

References


Revision History:
Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 6/29/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>